Study hints at role of stem cell genes in testicular, breast cancers

November 29, 2005

UCSF scientists have discovered that the activity of several embryonic stem cell genes is elevated in testicular and breast cancers, providing some of the first molecular evidence of a link between embryonic stem cells and cancer.

The finding, reported in the November issue of Cancer, suggests that the genes may play a role in the development of tumors or serve as valuable markers of tumor progression, the researchers say. As such, the genes ultimately could lead to new targets for therapy or markers for diagnosis.

A next step, according to the researchers, will be to "dig deeper" to determine the functions of the genes in the cells that make up the tumors.

Another step will be to explore whether the genes are expressed in other cancers, such as prostate cancer.

The genes are known as OCT 4, NANOG, STELLAR and GDF3.

The researchers focused on seminomas - tumors that account for 50 percent of the cases of testicular cancer, the most frequent cancer in Caucasian males ages 15-40 -- and breast cancers, as represented by a sample of breast cancer cells grown in the culture dish and tissue from a Stage 3 breast tumor.

Previously, the team had discovered that expression of the genes was elevated in two samples of seminomas (Stem Cells, March 2004). In the current study, they expanded their investigation, determining that the expression of the genes was elevated, at varying levels, in nine seminomas.

In the process, they identified the "window" during which seminomas begin to develop. Scientists have known that seminomas arise in sperm-producing germ cells, which are located in the testis and produce sperm in boys following puberty. Germ cells, like all cells of the body, develop from embryonic stem cells, and go through a multi-stage evolution in their structure and genetic activity before attaining their mature state. The study revealed that the genetic misregulation leading to seminomas begins very early in the formation of sperm-producing germ cells.

Next, turning to cancerous tissue outside of the reproductive system, in this case breast tissue, the team determined, to their surprise, that the expression of the genes was active there, too.

"We thought this was going to be a phenomenon unique to germ cell tumors," says the senior author of the study, Amander Clark, PhD, assistant research geneticist in the laboratory of co-author Renee Reijo Pera, PhD, associate professor of obstetrics, gynecology and reproductive sciences and co-director of the UCSF Human Embryonic Stem Cell Center.

"This is the first indication that these genes are markers of breast cancer. The finding might lead to information about where breast cancers come from," Clark adds. "Are they derived from an original stem cell population, one that is expressing these genes, or do the cells in the tumor represent normal cells that have reverted to a more embryonic state that would express these genes?"

The suggestion that embryonic stem cell genes play a role in some cancers is not surprising. Embryonic stem cells, which emerge in the first five to seven days of the embryo's development, undergo a series of steps in which they selectively "turn on," or "express," genes that cause the cells progressively to assume the characteristics of a particular cell type, such as that of the skin, heart or brain. Cancers, meanwhile, develop when particular genes that regulate cell growth become misregulated, leading a cell to begin proliferating excessively. Misregulated embryonic stem cell genes, scientists have reasoned, could cause or advance cancer.

Substantial evidence already suggests, in fact, that genes in adult stem cells - which reside in many tissues of the body - cause some leukemias, and that they may cause gliomas, the most common form of brain tumor (UCSF - Nature, Feb. 19, 2004 ; UCSF - New England Journal of Medicine, Aug. 25, 2005).

The current study evolved from ongoing research in the Reijo Pera lab aimed at identifying the genes that lead human embryonic stem cells to evolve into early-stage germ cells, and ultimately to specialize as sperm-producing cells or eggs, or "ooctyes." The goal of this research is to identify the genetic missteps that lead to birth defects and infertility.

As part of this research, the team had determined that the four genes - OCT 4, NANOG, STELLAR and GDF3-- play a role in prompting human embryonic stem cells to develop into primordial, or earliest-stage, germ cells. Three of these genes -- NANOG, STELLAR and GDF3 - are located on chromosome 12, at a site designated 12p13.

Because seminoma cells resemble these early-stage cells in structure, and have duplications in genetic material on chromosome 12p13 that are associated with invasive seminoma (though no genes have been linked to the malignancy), the team had subsequently investigated two samples of seminomas, to see if the genes were expressed at elevated levels. They were, as was OCT 4.

The current study demonstrated that the four genes had elevated expressions in the nine seminoma samples examined, when compared with normal testis tissue. GDF3 was elevated in 90 percent of cases, OCT4 was elevated in 56 percent of cases and NANOG and STELLAR expression were elevated in 33 percent of cases.

The team also examined the relative expression of these genes, and four other genes that play an important role in normal testis, in the nine samples. OCT 4 and NANOG were the highest expressed genes in each of the seminoma samples.

The variability of the genes' expression within the very earliest stage of germ cell tumor progression, says Clark, "could tell us something about the potential for these tumors to metastasize."

Finally, they examined breast cancer tissue and normal breast tissue. While normal tissue did not express detectable levels of the genes, both the breast carcinoma cell lines and stage 3 breast carcinoma expressed all four genes.

The scientists suspect that expression of the genes may be elevated in other non-reproductive cancers, as well, such as those of the prostate. Studies have shown, says Clark, that OCT 4, which works with NANOG to regulate the capacity of cells to specialize, causes dysplatic lesions in the intestines, skin and stomach. "It would be useful to look at NANOG in those places where we know over expression of OCT 4 results in tumor progression," she says. "It may be playing a role there, too."

Other co-authors of the study were Uche I. Ezeh, MD, UCSF clinical instructor of physiology, and Paul J. Turek, MD, UCSF associate professor of urology.
-end-
The study was funded by the Lance Armstrong Foundation and the National Institutes of Health.

UCSF is a leading university that consistently defines health care worldwide by conducting advanced biomedical research, educating graduate students in the life sciences, and providing complex patient care.

University of California - San Francisco

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.